Comparative in vitro activity of l-ofloxacin and FK037 to other agents against 10,040 fresh clinical isolates.
Fresh clinical isolates collected from November 1, 1992 through November 1, 1993, were tested by agar dilution against 26 different antimicrobial agents including FK037 and l-ofloxacin. Among the 10 040 organisms tested were Staphylococcus aureus (n = 1222), methicillin-resistant Staphylococcus aureus (MRSA, n = 455), Staphylococcus epidermidis (n = 533), Staphylococcus hominis (n = 90), Staphylococcus hemolyticus (n = 89), Streptococcus pneumoniae (n = 144), Escherichia coli (n = 2326), Klebsiella pneumoniae (n = 745), Enterobacter cloacae (n = 258), Proteus mirabilis (n = 445), Pseudomonas aeruginosa (n = 998), and Stenotrophomonas (Xanthomonas) maltophilia (n = 102). Both l-ofloxacin and FK037 inhibited 98% of S. aureus strains at 4 mug/ml. FK037 was at least 4 times more effective than the third generation cephalosporins against MRSA, inhibiting 79% of the strains at 16 mug/ml. While the potency of these agents looks promising, their clinical utility will depend in part upon the maximal dosage that can be safely administered.
Cooper
I
I
Clinical Microbiology Section, Pathology Department, Northwestern Memorial Hospital, Northwestern University Medical School, Wesley Pavilion, Room 565, 250 E. Superior Street, Chicago, IL 60611, USA.
Isbell
D J
DJ
Kruszynski
J A
JA
Peterson
L R
LR